Suresh S. Ramalingam, MD, on Osimertinib vs Comparator EGFR TKI in EGFR-Mutated NSCLC: The FLAURA Trial
ESMO 2019 Congress
Suresh S. Ramalingam, MD, of Emory University, discusses results from the final overall survival analysis of the phase III FLAURA trial in EGFR-mutated advanced non–small cell lung cancer, which showed that osimertinib provided a survival benefit vs comparator EGFR tyrosine kinase inhibitor therapy in the first-line setting (Abstract LBA5).
Antonio González Martín, MD, PhD, of the Clínica Universidad de Navarra, discusses study findings showing niraparib therapy significantly improved progression-free survival in patients with advanced ovarian cancer across biomarker subgroups (Abstract LBA1).
Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, which showed that by adding veliparib to front-line carboplatin and paclitaxel and continuing it as monotherapy maintenance, the PARP inhibitor extended progression-free survival in women with newly diagnosed high-grade serous carcinoma of the ovaries or fallopian tubes or tumors of primary peritoneal origin (Abstract LBA3).
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss overall survival in this phase II study of atezolizumab/trastuzumab emtansine (T-DM1) vs placebo/T-DM1 in previously treated HER2-positive advanced breast cancer (Abstract 305O).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without docetaxel in patients with prostate cancer with only lymph node metastases or less than four bone metastases (Abstract 844O).
Ana Maria Arance Fernandez, MD, PhD, of the Hospital Clínic de Barcelona, discusses the negative results of the phase III IMspire170 trial, which evaluated cobimetinib/atezolizumab vs pembrolizumab monotherapy in patients with BRAF V600 wild-type melanoma (Abstract LBA69).
